IFNG and tuberculosis: We have recently shown that the IFN-γ dose–response curve in mice, for the novel TB vaccine H56 + IC31, was peaked, not saturating,7 and an ongoing phase 1/2a H56 + IC31 dose-ranging clinical trial will test this prediction in humans (ClinicalTrials.gov No. NCT01865487).